BI calls it quits in hep. C

Share this article:

Boeheringer Ingelheim is officially out of the hepatitis C space. The Connecticut drugmaker announced Friday that it was killing its faldaprevir interferon-based regimen because “there is no longer an unmet medical need” for this treatment.

The company hinted at such a move in April when it said Phase III results of its faldaprevir-deleobuvir combination “did not live up to expectations,” and that these results were prompting the firm to examine “its activities in the field of hepatitis C therapy in depth.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.